Target intelligence / Profile preview

Smooth muscle cell (SMC) (SMC)

Target
SMC
Molecular classification
Other
01

Overview

Smooth muscle cells (SMCs) are specialized, spindle-shaped cells that lack the striations characteristic of skeletal and cardiac muscle. They are found within the walls of various internal organs and structures, including the vasculature, respiratory airways, digestive tract, and urogenital system, where they perform involuntary movements. The primary function of SMCs is to regulate the diameter and tone of these hollow structures through contraction and relaxation, driven by changes in intracellular calcium levels and the interaction of actin and myosin filaments (StatPearls, 2023). In pathological conditions, SMCs can undergo phenotypic switching from a contractile to a synthetic state, contributing to diseases such as atherosclerosis, hypertension, and asthma (Nature Reviews Cardiology, 2015). Therapeutic strategies often focus on modulating SMC tone using drugs like calcium channel blockers or bronchodilators, which target specific proteins on the cell surface or within the cytoplasm to manage cardiovascular and respiratory conditions. Because SMCs are ubiquitous throughout the body, a major challenge in drug development is achieving tissue-specific effects to avoid systemic side effects like hypotension or digestive issues.

Other names
SMCInvoluntary muscle cellNon-striated muscle cell
02

Mechanism of action

Pharmacological agents modulate smooth muscle cell function by interacting with specific molecular targets such as G protein-coupled receptors (GPCRs), ion channels, or enzymes (e.g., phosphodiesterases) to alter intracellular calcium concentrations or the sensitivity of the contractile apparatus to calcium (StatPearls, 2023).

03

Biological functions

ContractionVasoconstrictionVasodilationPeristalsisBronchoconstrictionExtracellular matrix production
04

Disease associations

HypertensionAsthmaAtherosclerosisCardiovascular diseaseChronic obstructive pulmonary disease (COPD)
05

Safety considerations

Systemic hypotensionReflex tachycardiaGastrointestinal motility disturbancesLack of tissue specificity leading to off-target effects in non-target organs
06

Interacting drugs

Amlodipine

5 more in the full profile.

07

Biomarkers

Alpha-smooth muscle actin (ACTA2)Smooth muscle myosin heavy chain (MYH11)Calponin (CNN1)Transgelin (TAGLN/SM22-alpha)

Beyond the preview

Go deeper on Smooth muscle cell (SMC) (SMC).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Smooth muscle cell (SMC) (SMC).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call